Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Over ten years, you are approaching $150,000
Biosimilar development is the medium-term democratization opportunity Biocon Biologics, Samsung Bioepis, and other biosimilar developers are advancing semaglutide biosimilar programs that, upon patent expiry, could reduce drug costs by 70-85% and dramatically expand patient access in both developed markets with coverage barriers and developing markets with affordability constraints
Lu S, Wu J, Jiang J, Guo Q, Yu Y, Liu Y, et al
What to Avoid : Never reuse needles, as this can increase the risk of infection
US$ 24.64
US$ 29.18
US$ 28.88
US$ 28.18
